We are an AI-powered drug discovery startup that is revolutionizing the way new drugs can be discovered.

We combine deep proteomics with machine learning to better combat complex diseases and create a healthier world.

proteinprotein

Tech Meets Science

To open the bottlenecks of discovery, we rely on the talent intersection of cutting-edge biology, proteomics, powerful software, and machine learning capabilities. This has been our compass for building our company from day one.

Protai team

Founders

Eran Seger, CEO, Protai
Eran Seger
 - 
CEO
linkdein
Kirill Pevzner, CTO, Protai
Kirill Pevzner
 - 
CTO
linkdein

Our Team

Alon Shtrikman
Alon Shtrikman
BIOLOGICAL RESEARCHER
linkdein
Amit Manor, Medical Data Analyst
, Protai
Amit Manor
Medical Data Analyst
linkdein
Andy Morley - Medicinal Chemisrty
Andy Morley
Medicinal Chemisrty
linkdein
ANJANA SHENOY KATAPADI
Anjana Shenoy Katapadi
PROTEOMICS SCIENTIST
linkdein
Avital Hay-Koren, Biological Researcher
, Protai
Avital Hay-Koren
Biological Researcher
linkdein
BARR TIVON
Barr Tivon
COMPUTATIONAL CHEMIST
linkdein
Dimitri Kovalerchik, Mass spectrometry scientist
, Protai
Dimitri Kovalerchik
Mass spectrometry scientist
linkdein
Dina Daitchman - SOFTWARE & ALGORITHMS
Dina Daitchman
SOFTWARE & ALGORITHMS
linkdein
Elyad Lezmi - Systems biologist
Elyad Lezmi
Systems biologist
linkdein
Fabrizio Fierro - Computational Chemist
Fabrizio Fierro
Computational Chemist
linkdein
Gali Arad, Computational proteomics, Protai
Gali Arad
HEAD OF SYSTEMS BIOLOGY
linkdein
GALINA OTONIN
Galina Otonin
RESEARCH ASSOCIATE
linkdein
Iris Alchanati, Lab Manager
, Protai
Iris Alchanati
Lab Manager
linkdein
Nitzan Simchi, Software & algorithms, Protai
Nitzan Simchi
HEAD OF SOFTWARE & ALGORITHMS
linkdein
Ofer Givton - Biomedical data analyst
Ofer Givton
Biomedical data analyst
linkdein
SHAY HERMAN
Shay Herman
BIOLOGICAL RESEARCHER
linkdein
Yael Schachter, Administration Manager
, Protai
Yael Schachter
OPERATIONS MANAGER
linkdein
Yonatan Katzenelenbogen - Systems biologist
Yonatan Katzenelenbogen
Systems biologist
linkdein

Backed by mission-driven funds

Our advisors

Dr. Giulio Draetta, Chief Scientific officer of M.D. Anderson , Protai
Dr. Giulio Draetta
Chief Scientific officer of M.D. Anderson

Prof. Giulio Draetta, M.D., Ph.D., is senior vice president and chief scientific officer at The University of Texas MD Anderson Cancer Center. Prof. Draetta is also a member of MD Anderson’s faculty as a professor of Genomic Medicine and the Sewell Family Distinguished University Chair. As chief scientific officer, he provides focused leadership for the institution’s diverse scientific and clinical research faculty, championing innovation and team science, and fostering strong partnerships with the cancer research community worldwide.

Dr. Giulio Draetta

Prof. Giulio Draetta, M.D., Ph.D., is senior vice president and chief scientific officer at The University of Texas MD Anderson Cancer Center. Prof. Draetta is also a member of MD Anderson’s faculty as a professor of Genomic Medicine and the Sewell Family Distinguished University Chair. As chief scientific officer, he provides focused leadership for the institution’s diverse scientific and clinical research faculty, championing innovation and team science, and fostering strong partnerships with the cancer research community worldwide.

University of Texas MD Anderson Cancer Center. Dr. Draetta
arrow
Prof. Tami Geiger, Clinical cancer proteomics, Protai
Prof. Tami Geiger
Clinical cancer proteomics

Prof Tami Geiger from the Weizmann Institute of Science, is a world leader in clinical cancer proteomics. Her lab uses state of the art mass spectrometry-based proteomics technology to study cancer progression and drug resistance mechanisms. Her research combines proteomic method development with basic biological research and bioinformatics. Ultimately, her research aims toward cancer biomarker discovery, and provides better understanding of cancer transformation processes.

Prof. Tami Geiger

Prof Tami Geiger from the Weizmann Institute of Science, is a world leader in clinical cancer proteomics. Her lab uses state of the art mass spectrometry-based proteomics technology to study cancer progression and drug resistance mechanisms. Her research combines proteomic method development with basic biological research and bioinformatics. Ultimately, her research aims toward cancer biomarker discovery, and provides better understanding of cancer transformation processes.

Weizmann Institute of science
arrow
Dr. Sharon Shacham, Serial entrepreneur in biotech and climate, Protai
Dr. Sharon Shacham
Serial entrepreneur in biotech and climate

Dr. Shacham is a serial entrepreneur in the fields of Biotech and climate. Dr. Shacham is currently a co-founder and general partner at E44 Ventures, a new studio venture focused on partnering with academia and early ideators, to build technology-based companies to contribute to a cleaner, more sustainable future for our planet. Prior to that, Dr. Shacham founded Karyopharm Therapeutics (NASDAQ: KPTI) where she created the novel oral cancer drug Xpovio® , and led its development from idea to commercialization: Xpovio is now approved worldwide.

Dr. Sharon Shacham

Dr. Shacham is a serial entrepreneur in the fields of Biotech and climate. Dr. Shacham is currently a co-founder and general partner at E44 Ventures, a new studio venture focused on partnering with academia and early ideators, to build technology-based companies to contribute to a cleaner, more sustainable future for our planet. Prior to that, Dr. Shacham founded Karyopharm Therapeutics (NASDAQ: KPTI) where she created the novel oral cancer drug Xpovio® , and led its development from idea to commercialization: Xpovio is now approved worldwide.

Karyopharm therapeutics
arrow
Prof. Funda Meric-Bernstam, Head of Phase 1 unit of MD Anderson, Protai
Prof. Funda Meric-Bernstam
Head of Phase 1 unit of MD Anderson

Prof. Funda Meric-Bernstam has made internationally recognized contributions to precision oncology. As leader of one of the largest Phase I programs in the world, she has focused drug development on identifying single agents and combinations of drugs that target subsets of cancers from multiple sites with innovative basket trials.

Prof. Funda Meric-Bernstam

Prof. Funda Meric-Bernstam has made internationally recognized contributions to precision oncology. As leader of one of the largest Phase I programs in the world, she has focused drug development on identifying single agents and combinations of drugs that target subsets of cancers from multiple sites with innovative basket trials.

Department of Investigational Cancer Therapeutics
arrow
Prof. Bradley J. Monk, Clinical trialist, drug developer and translational scientist in gyno-oncologyת Protai
Prof. Bradley J. Monk
Clinical trialist, drug developer and translational scientist in gyno-oncology

Prof. Bradley Monk from the department of Gynecology at the University of Arizona College of Medicine in Phoenix, Arizona, is an established clinical trialist, drug developer and translational scientist in gynecologic cancers. He has authored and co-authored hundreds of peer reviewed publications, and has focused his research on gynecologic surgery-complex, cervical cancer, ovarian cancer, and other gynecologic cancers.

Prof. Bradley J. Monk

Prof. Bradley Monk from the department of Gynecology at the University of Arizona College of Medicine in Phoenix, Arizona, is an established clinical trialist, drug developer and translational scientist in gynecologic cancers. He has authored and co-authored hundreds of peer reviewed publications, and has focused his research on gynecologic surgery-complex, cervical cancer, ovarian cancer, and other gynecologic cancers.

University of Arizona College of Medicine
arrow
Dr. Jurgen Moll, Pharma veteran with leadership positions at SANOFI, BI and Pfizer, Protai
Dr. Jurgen Moll
Pharma veteran with leadership positions at SANOFI, BI and Pfizer

Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.

Dr. Jurgen Moll

Dr. Moll is a serial drug hunter focused on cancer research and preclinical development with over twenty years experience in leadership positions in big pharma such as Pharmacia, Pfizer, Boehringer-Ingelheim, and Sanofi. His expertise lies in both cancer cell targeted and IO assets, using different modalities such as small molecules, antibodies and nanobodies. He has a proven track record of initiating and progressing targets and drugs in Oncology.

Sanofi - innovative global healthcare company
arrow
Prof. Avi Ma’ayan, Computational systems biology, Protai
Prof. Avi Ma’ayan
Computational systems biology

Prof. Ma’ayan is a Mount Sinai Endowed Professor in Bioinformatics, Professor in the Department of Pharmacological Sciences, and Director of the Mount Sinai Center for Bioinformatics. The Ma'ayan Laboratory develops computational tools to study the complexity of regulatory networks in mammalian cells. Professor Ma’ayan lab is one of the world leading groups in ML driven tools and analysis for proteomics and post-translational-modification data for translational research.

Prof. Avi Ma’ayan

Prof. Ma’ayan is a Mount Sinai Endowed Professor in Bioinformatics, Professor in the Department of Pharmacological Sciences, and Director of the Mount Sinai Center for Bioinformatics. The Ma'ayan Laboratory develops computational tools to study the complexity of regulatory networks in mammalian cells. Professor Ma’ayan lab is one of the world leading groups in ML driven tools and analysis for proteomics and post-translational-modification data for translational research.

Icahn School of Medicine at Mount Sinai
arrow
Prof. Alexey I. Nesvizhskii, Computational Proteomics , Protai
Prof. Alexey I. Nesvizhskii
Computational Proteomics

Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues are used by thousands of laboratories worldwide

Prof. Alexey I. Nesvizhskii

Alexey Nesvizhskii is endowed Godfrey Dorr Stobbe Professor of Bioinformatics in the Departments of Pathology and Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor. His research laboratory is working in the areas of mass spectrometry-based proteomics and proteogenomics, bioinformatics, and multi-omics data integration. The computational methods and tools developed by Dr. Nesvizhskii and his colleagues are used by thousands of laboratories worldwide

Department of Pathology. University of Michigan Medical School.
arrow
Want to join the team?

Check out open positions

Open positions

Let's talk

Get in touch with us for questions and potential collaborations.